About InterMune
InterMune is a Healthcare company based in Brisbane (United States) founded in 1998, and was acquired by Legacy Pharma in February 2025. Therapies in pulmonology and orphan fibrotic diseases. The company has 359 employees. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its competitors include aTyr Pharma, ReCode Therapeutics and GEn1E; 3 of its 3 listed competitors have raised funding.
Company details
InterMune was founded in 1998 and is headquartered in Brisbane, United States. Operations in the biotechnology sector center on research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases. Idiopathic pulmonary fibrosis is addressed through Pirfenidone, approved in the EU as Esbriet and under Phase 3 trials for U.S. registration. Small-molecule therapeutics and biomarkers are pursued for monitoring serious pulmonary conditions.
- Headquarters Brisbane, United States
- Employees 359
- Stage Acquired
- SectorsHealthcare
- Website intermune.com
- Social LinkedIn
- Acquired by Legacy Pharma (Feb 2025)
- InvestorsRoche
& 1 more
- Employee Count359
- Acquired by
Investors in InterMune
InterMune has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Roche and Legacy Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland | |
Legacy Pharma is engaged in distributing prescription pharmaceutical products. | legacypharmainc.com | George Town, Grand Cayman |
Investor details for InterMune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of InterMune
1 people are tracked at InterMune (1 in leadership); the tracked headcount is 359.
| Name | Role | Group |
|---|---|---|
Dan Welch | Chairman, Chief Executive Officer and President | Leadership |
Complete people profiles for InterMune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of InterMune
4 dated milestones of InterMune across 27 years, from founding to its latest funding, stage changes and deals.
- Founded InterMune is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Roche.
- Exit Acquired by Legacy Pharma.
Competitors of InterMune
InterMune has 3 listed competitors in our database, 3 of them funded. They include aTyr Pharma, ReCode Therapeutics and GEn1E.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | Precision medicines for lung-related diseases are developed. | ||
| gen1e.com | 2018 | Palo Alto, United States | $17.15M | Developer of therapeutics for the treatment of inflammatory and rare diseases |
Detailed competitors of InterMune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of InterMune
Websites that share an audience with InterMune (intermune.com).
Websites whose visitors overlap most with InterMune. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| exelixis.com | 100% | 39.1K | #1,001,350 | View details | |
| osip.com | 97% | View details | |||
precisiontherapeutics.com | precisiontherapeutics.com | 82% | – | ||
| keryx.com | 82% | View details | |||
| kingpharm.com | 82% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for InterMune
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as InterMune (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intermune
Complete news archive for InterMune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InterMune
InterMune was founded in 1998.
InterMune is headquartered in Brisbane, United States. It is registered at Brisbane, California, United States.
InterMune has 359 employees.
InterMune was founded in 1998 and is headquartered in Brisbane, United States. Operations in the biotechnology sector center on research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases. Idiopathic pulmonary fibrosis is addressed through Pirfenidone, approved in the EU as Esbriet and under Phase 3 trials for U.S. registration. Small-molecule therapeutics and biomarkers are pursued for monitoring serious pulmonary conditions.
InterMune's top competitors include aTyr Pharma, ReCode Therapeutics and GEn1E.
InterMune has 2 investors. Key investors include Roche, and Legacy Pharma.
Yes. InterMune was acquired by Legacy Pharma in February 2025.